The Scary Headline vs. the Data
A few years ago, reports of mood changes and suicidal thoughts in people taking GLP-1 drugs began circulating. Regulators took notice. The European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) both reviewed the concern. A new systematic review in the Rambam Maimonides Medical Journal now pulls the evidence together, and the headline finding is reassuring: randomized trial evidence shows no increased risk of suicidality, depression, or anxiety with GLP-1 receptor agonists (like semaglutide) or tirzepatide.
The full picture has caveats, though, and they matter.
- Paper: Jani HT, Levine H, Patel A, Trivedi R, Patel XD. Neuropsychiatric Safety of GLP-1 Receptor Agonists and Tirzepatide in Adults with Type 2 Diabetes Mellitus or Obesity. Rambam Maimonides Med J, 2026.
- PubMed: https://pubmed.ncbi.nlm.nih.gov/42957176/
- DOI: https://doi.org/10.5041/rmmj.10585
What the Researchers Did
The authors searched PubMed/MEDLINE, Embase, Web of Science, and Scopus through March 15, 2026, limited to English-language studies in adults aged 18 and over with type 2 diabetes or obesity. They followed PRISMA 2020 reporting standards, plus the PRISMA-S and PRISMA-Harms extensions. In all, 20 studies and two regulatory reviews met the inclusion criteria.
The evidence was sorted into prespecified groups:
- Randomized syntheses
- Comparative observational studies and target-trial emulations
- Outlier studies without an active comparator
- Pharmacovigilance (adverse-event reporting) analyses
- Regulatory reviews
The authors appraised bias with Cochrane's RoB 2 tool and ROBINS-I, and summarized certainty using GRADE. They emphasized the difference between signal detection (something looks off in the data) and causal inference (the drug actually did it).
The Key Findings, Scannable
Randomized evidence: no increased risk
The strongest evidence came from randomized trials, including two large 2025 meta-analyses and post hoc pooled analyses of semaglutide and tirzepatide. None showed increased suicidality, depression, or anxiety.
Real-world cohorts: no clear increase
Active-comparator cohort studies from the United States, Scandinavia, and the United Kingdom also found no clear increase after controlling for confounding. Active-comparator designs match GLP-1 users against people on other diabetes or weight-loss drugs, which makes the comparison fairer.
Where the alarming signals came from
Passive-comparator studies and disproportionality analyses did generate signals. According to the review, these designs could not separate drug effects from three other explanations:
- Baseline psychiatric risk
- Distress related to obesity
- Reporting bias
These designs are useful for raising questions, but they are weak at answering them. People living with obesity already have higher rates of depression and anxiety, so a raw comparison against people without these conditions can mislead.
Regulators: no causal class-wide link
The EMA and FDA conclusions, as summarized by the authors, do not support a causal class-wide association between GLP-1 RAs and suicidal ideation or behavior.
The Fine Print: Why This Isn't a Blank Check
The authors conclude that evidence does not support a clinically meaningful increase in neuropsychiatric harm in the populations studied. The wording is deliberate, and several limitations apply:
- Trials excluded people with psychiatric illness. The review notes that psychiatric exclusion criteria limited generalizability. The people most worried about mood effects are often the ones least represented in the randomized data.
- Rare, long-term outcomes remain uncertain. Surveillance is still warranted here.
- Obesity-only populations are flagged for continued monitoring.
- Patients with substantial psychiatric morbidity are also flagged for surveillance.
- Observational data can't fully eliminate confounding, even with modern methods.
- The review is limited to English-language studies in adults with type 2 diabetes or obesity. It does not address children or other conditions.
Practical Takeaways
This is a safety review of prescription drugs, not a study of a supplement. It tested no doses or timing strategies, so it offers no dosing or timing guidance. Your prescriber's instructions and the product label are the right source for that.
What the evidence supports:
- If you are an adult with type 2 diabetes or obesity, current evidence does not show that semaglutide or tirzepatide (the active ingredients in Ozempic/Wegovy and Mounjaro/Zepbound) raises the risk of depression, anxiety, or suicidality.
- Mood changes during rapid weight loss can still happen for many reasons. Report them rather than assuming they are harmless or drug-caused.
Who should pay extra attention:
- People with a history of significant psychiatric illness, since they were underrepresented in trials. The review calls for ongoing surveillance in this group, not avoidance.
- People using these drugs for obesity alone, a population the authors flag for continued monitoring.
Who should skip it? The review does not identify any group that should avoid these drugs on neuropsychiatric grounds. Whether a GLP-1 drug is right for you depends on your full medical history and is a decision for you and your clinician.
If you notice new or worsening low mood, anxiety, or thoughts of self-harm, contact your healthcare provider promptly. In the US, you can call or text 988 for the Suicide & Crisis Lifeline. Don't stop or change your medication on your own without medical advice.
Bottom Line
The best-controlled evidence points the same way: no increased suicidality, depression, or anxiety, and no regulator-confirmed causal link. The frightening signals trace largely to study designs that can't untangle drug effects from pre-existing risk and reporting bias. The remaining questions concern patients with serious psychiatric histories and very rare, long-term outcomes. For those, the honest answer is that monitoring should continue.
This article summarizes a published review and is not medical advice.